USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BIOMEDICAL RESEARCH MODELS, INC.
Address:
67 MILLBROOK, ST, STE 422
WORCESTER, MA
Phone:
N/A
URL:
N/A
EIN:
43338250
DUNS:
15341134
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $4,102,923.00 11
SBIR Phase II $3,015,625.00 2
STTR Phase I $1,225,087.00 4

Award List:

NEW RAT MODEL OF OBESITY AND TYPE II DIABETES

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$99,904.00
Agency:
HHS
Principal Investigator:
Guberski, dennis l
Abstract:
N/a

CRYOPRESERVATION OF THE BB/WOR RAT

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$85,254.00
Agency:
HHS
Principal Investigator:
Kislauskis, edward h
Abstract:
N/a

EARLY BIOMARKER CHANGES IN DIABETIC NEPHROPATHY

Award Year / Program / Phase:
1999 / STTR / Phase I
Award Amount:
$98,990.00
Agency:
HHS
Principal Investigator:
Hemstreet
Research Institution:
University of Oklahoma
RI Contact:
N/A
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$123,148.00
Agency:
HHS
Principal Investigator:
Edward H. Kislauskis
Abstract:
N/a

THE BBZDR RAT, NEW MODEL OF OBESITY/TYPE 2 DIABETES

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Dennis L. Guberski
Abstract:
N/a

THE BBZDR RAT, NEW MODEL OF OBESITY/TYPE 2 DIABETES

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$452,092.00
Agency:
HHS
Principal Investigator:
Dennis L. Guberski
Abstract:
N/a

New Rat Model of Autoimmune Diabetes And Arthritis

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$171,353.00
Agency:
HHS
Principal Investigator:
Dennis L. Guberski
Abstract:
DESCRIPTION (provided by applicant): The objectives of this proposal are to develop and characterize a new congenic rat model with spontaneous autoimmune disease. In Phase 1 we will establish a foundation colony of LEW.1WR1 rats and begin genetic crosses to introgress traits… More

Engineering Myoblasts for Transplantation

Award Year / Program / Phase:
2004 / STTR / Phase I
Award Amount:
$223,141.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF MASSACHUSETTS AMHERST
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The primary goals of stem cell biology are to develop practical cell-based tools: 1) to enhance the repair of damaged organs and tissues; and 2) as vehicles for gene therapy to introduce engineered genes to the body to either correct a genetic defect or to… More

In-Stent Stenosis Model in Type 2 Diabetic Rats

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$393,589.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Coronary artery disease affects 12 million Americans and is the number on killer in the United States. Diabetes affects over 16 million Americans, with more than 80,000 new cases diagnosed each year. Cardiovascular complications of diabetes kills 75% of… More

Neurogenic Compounds for Treating Diabetic Complications

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$1,000,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Neuronal dysfunction is the leading complication associated with diabetes. Diabetic patients experience both cognitive impairment and a collection of syndromes termed "diabetic neuropathies". Although many of the pathways involved in initiating… More

A Mucosal Vaccine for HSV-2

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$583,103.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Approximately 1 out of every 5 Americans is infected with herpes simplex virus type 2 (HSV-2). Localized genital infection by HSV-2 results in painful recurring genital lesions while disseminated infection can involve multiple visceral organs and lethal… More

A Mucosal Vaccine for HSV-2

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$2,563,533.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Approximately 1 out of every 5 Americans is infected with herpes simplex virus type 2 (HSV-2). Localized genital infection by HSV-2 results in painful recurring genital lesions while disseminated infection can involve m ultiple visceral organs and lethal… More

New Rat Model For Autoimmune Therapy Safety/Efficacy

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$594,141.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Autoimmune diseases comprise the third most common category of illness in the United States affecting an estimated 22 million Americans. To date, therapeutic and preventive strategies for human autoimmune diseases (b ased on the restoration of immune… More

Developing small molecule therapeutics for lupus

Award Year / Program / Phase:
2011 / STTR / Phase I
Award Amount:
$583,195.00
Agency:
HHS
Principal Investigator:
Thomas R. Coleman – 508-459-7544
Research Institution:
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Systemic lupus erythematosus (SLE) affects ~ 2 million Americans with devastating impact on multiple organs, especially the skin, joints, kidney, and brain. Therapeutic strategies for lupus are largely palliative orimmunosuppressive with serious toxicities.… More

A Mucosal RSV Vaccine

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Kejian Yang – 508-459-7544
Abstract:
DESCRIPTION (provided by applicant): Human respiratory syncytial virus (RSV) is a highly infectious member of the paramyxovirus family causing upper and lower respiratory tract infections. RSV infection is the leading cause of pulmonary disease of the lower respiratory tract (bronchiolitis,… More

Developing Small MIF Inhibitors for Rheumatoid Arthritis

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$452,431.00
Agency:
HHS
Principal Investigator:
Barbara Whalen – 508-459-7544
Abstract:
DESCRIPTION (provided by applicant): Rheumatoid arthritis is a chronic inflammatory disorder that afflicts at least 2.5 million Americans. This autoimmune disease is 2-3 times more common in women and typically affects the small joints in the hands and feet. Current therapeutic strategies include… More